(Q42646662)

4 November 2017

title

Beta-glucan-CRM197 conjugates as candidates antifungal vaccines (English)

1 reference

4 November 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

6364

[3)-beta-D-Glcp-(1->]15

1 reference

beta-Glcp-(1->6)-{beta-Glcp-(1->6)-{[beta-Glcp-(1->3)]5}-[beta-Glcp-(1->3)]5}-[beta-Glcp-(1->3)]4-beta-Glcp

ChEBI release 2020-05-28

ChEBI ID

62312

1 reference

ChEBI release 2020-05-28

10

Rino Rappuoli

1 reference

4 November 2017

11

Antonio Cassone

1 reference

4 November 2017

Carla Bromuro

1

1 reference

4 November 2017

Maria Romano

2

1 reference

4 November 2017

Paola Chiani

3

1 reference

4 November 2017

Francesco Berti

4

1 reference

4 November 2017

Marta Tontini

5

1 reference

4 November 2017

Daniela Proietti

6

1 reference

4 November 2017

Elena Mori

7

1 reference

4 November 2017

Antonella Torosantucci

8

1 reference

4 November 2017

Paolo Costantino

9

1 reference

4 November 2017

language of work or name

English

0 references

publication date

21 January 2010

1 reference

4 November 2017

1 reference

4 November 2017

volume

28

1 reference

4 November 2017

issue

14

1 reference

4 November 2017

page(s)

2615-2623

1 reference

Invasive aspergillosis in critically ill patients without malignancy

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Epidemiology of invasive candidiasis: a persistent public health problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Fungal vaccines: real progress from real challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Advances in combating fungal diseases: vaccines on the threshold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Prospects for development of vaccines against fungal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Is a vaccine needed against Candida albicans?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

The structure and synthesis of the fungal cell wall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

A novel glyco-conjugate vaccine against fungal pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Analysis of the structural heterogeneity of laminarin by electrospray-ionisation-mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Ultraviolet spectrophotometric determination of hexoses, pentoses, and uronic acids after their reactions with concentrated sulfuric acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Determination of free amino groups in proteins by trinitrobenzenesulfonic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

A spectrophotometric assay for soluble and immobilized N-hydroxysuccinimide esters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Structural characterization of beta-D-(1 --> 3, 1 --> 6)-linked glucans using NMR spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Curdlan and other bacterial (1-->3)-beta-D-glucans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Synthesis of glycoconjugate vaccines for Candida albicans using novel linker methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Synthesis and immunochemical studies on a Candida albicans cluster glycoconjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Candida albicans mannan-protein conjugate as vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Generating cell surface diversity in Candida albicans and other fungal pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Fungal β-Glucans and Mammalian Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

7 January 2021

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Anti-beta-glucan antibodies in healthy human subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

inferred from DOI database lookup

7 January 2021

based on heuristic

MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.01.012

1 reference

4 November 2017

1 reference